利拉鲁肽对稳定性慢性心力衰竭患者心肌葡萄糖摄取和血流的影响:一项双盲、随机、安慰剂对照的LIVE子研究
本研究为双盲随机安慰剂对照LIVE子研究,纳入左室射血分数≤45%且无2型糖尿病的慢性心力衰竭患者,随机接受利拉鲁肽1.8 mg每日一次(N=18)或安慰剂(N=18)治疗24周。采用18F-FDG和15O-H2O PET定量测量口服葡萄糖耐量试验期间心肌葡萄糖摄取变化及心肌血流和血流储备变化。结果显示利拉鲁肽降低体重、HbA1c和OGTT 2小时血糖,但两组间心肌葡萄糖摄取、心肌血流和血流储备变化无差异。
要点
- 利拉鲁肽1.8 mg每日一次治疗24周降低慢性心衰患者体重、HbA1c和OGTT 2小时血糖。
- 利拉鲁肽未影响非糖尿病慢性心衰患者的心肌葡萄糖摄取、心肌血流或血流储备。
- 基线胰岛素抵抗水平与利拉鲁肽治疗患者心肌葡萄糖摄取变化无关联。
核心结论
- 利拉鲁肽未影响非糖尿病慢性心力衰竭患者的心肌葡萄糖摄取、心肌血流或血流储备。
- 这些患者中任何潜在的心脏事件增加似乎不涉及心肌葡萄糖摄取、心肌血流或血流储备的变化。
研究设计与样本
- 双盲、随机、安慰剂对照的LIVE子研究,纳入左室射血分数≤45%且无2型糖尿病的慢性心力衰竭患者。
- 患者随机接受利拉鲁肽1.8 mg每日一次(N=18)或安慰剂(N=18)治疗24周。
- 采用18F-FDG和15O-H2O正电子发射断层扫描定量测量口服葡萄糖耐量试验期间心肌葡萄糖摄取变化及基线与随访间心肌血流和血流储备变化。
主要发现
- 与安慰剂相比,利拉鲁肽降低体重(P=0.03)、HbA1c(P=0.03)和OGTT 2小时血糖值(P=0.004)。
- 基线与随访间心肌葡萄糖摄取变化(P=0.98)、心肌血流变化(P=0.76)和血流储备变化(P=0.89)在两组间无差异。
- 在利拉鲁肽治疗患者中,基线胰岛素抵抗水平与心肌葡萄糖摄取变化之间无关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR). METHODS AND RESULTS: CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by 18F-FDG and 15O-H2O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide. CONCLUSION: Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR. TRIAL REGISTRATION: Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1.
引用
- Nielsen R, Jorsal A, Iversen P, et al. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. J Nucl Cardiol. 2017. PMID: 28770459. doi:10.1007/s12350-017-1000-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。